Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease. (12th February 2022)

• Record Type: Journal Article
• Authors: Bera, Arpita; Lavanya, Gantyada; Reshmi, Ravada; Dev, Kapil; Kumar, Rahul
• Other Names: Porsteinsson Anton P. guestEditor.; Rangaraju Srikant guestEditor.; Spires‐Jones Tara L. guestEditor.; O'Banion Kerry guestEditor.
• Is Part Of: European journal of neuroscience. Volume 56:Number 9(2022)
• Page Start: 5516
• Page End: 5531
• Publication Date: 2022-02-12
• Subjects: amyloid plaques -- Drp1 -- mitophagy -- neurodegeneration -- neurofibrillary tangles -- tau phosphorylation; Nervous system -- Periodicals; 612.8
• DOI: 10.1111/ejn.15611
• Languages: English
• ISSNs: 0953-816X

Abstract

Abstract: Alzheimer's disease (AD), a progressive neurodegenerative disorder, has emerged as the most common form of dementia in the elderly. Two major pathological hallmarks have been identified for AD: extracellular amyloid plaques and intracellular neurofibrillary tangles (NFT). Recently, dynamin‐related protein 1 (Drp1) was recognized to contribute significantly towards the pathogenesis of AD. Drp1 is primarily located in the cytosol, from where it translocates to the mitochondrial outer membrane and drives the mitochondrial fission via GTP hydrolysis. Drp1 interacts with Aβ and phosphorylated tau, leading to excessive mitochondrial fragmentation, which in turn results in synaptic dysfunction, neuronal damage and cognitive decline. Several studies suggest an increase in the level of Drp1 in the post‐mortem brain specimen collected from the AD patients and murine models of AD. Interestingly, heterozygous deletion of Drp1 in the transgenic murine model of AD ameliorates the mitochondrial dysfunction, improving learning and memory. The current review article discusses the possible mechanistic pathways by which Drp1 can influence the pathogenesis of AD. Besides, it will describe various inhibitors for Drp1 and their potential role as therapeutics for AD in the future.